＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.

＜Editors' Choice＞ How to improve outcomes of elderly patients with acute myeloid leukemia: era of excitement.
Nagoya J Med Sci. 2020 May;82(2):151-160
Authors: Tomoki N
Abstract
Among elderly patients with acute myeloid leukemia (AML), especially those who are unfit for intensive chemotherapy, a policy of reduced-intensity chemotherapy or conservative observation has been chosen, resulting in unmet medical needs. Clinical trials using anticancer drugs including antimetabolites or drugs targeted to cell cycle-related molecules failed to show superiority over conventional treatments. Recently, drugs targeted to Bcl-2, SMO, FLT3, and IDH1/2 have been shown to prolong overall survival alone or in combination with reduced-intensity chemotherapy. These treatments are likely to reshape the therapeutic landscape of AML, which will be personalized for individual patients based on leukemia genetics.
PMID: 32581396 [PubMed - in process]

Source: Nagoya Journal of Medical Science - June 27, 2020 Category: International Medicine & Public Health Tags: Nagoya J Med Sci Source Type: research